Drugs / VVD-130850
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06188208 | Jan 2024 → Feb 2026 | cancer, hematopoietic and lymphoid cell neoplasm | Vividion Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VVD-130850 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06188208 ↗ |
| Action | Inhibit | “STAT3 Inhibitor VVD-130850” NCT06188208 ↗ |
| Route | Oral | “Participants will receive ascending doses of VVD-130850, orally, once daily in 21-day treatment cycles during the dose escalation phase.” NCT06188208 ↗ |
| Target | STAT3 | “STAT3 Inhibitor VVD-130850” NCT06188208 ↗ |